BELLADONNA (Atropa belladonna L.)

BELLADONNA (Atropa belladonna L.)

Activities (Belladonna) — Analgesic (1; CRC; FNF); Anesthetic (1; LAF); Antiasthmatic (f; CRC);
Anticholinergic (1; KOM; PH2); Antidote (f; CRC); Antipyretic (f; CRC; EFS); Antisecretagogue
(f; CRC); Antispasmodic (1; APA; CRC; PNC); Antisialagogue (1; APA); Cardioactive (1; KOM);
CNS-Depressant (1; APA); CNS-Stimulant (1; APA); Collyrium (f; CRC); Diuretic (f; CRC; EFS);
Hallucinogen (1; PH2); Hypertensive (f; PNC); Laxative (f; CRC); Liniment (f; CRC); Mydriatic
(1; APA; CRC; PNC); Myorelaxant (1; APA; KOM; PH2); Narcotic (1; PNC); Nervine (f; CRC;
EFS); Parasympatholytic (1; KOM; PH2); Positive Chronotropic (1; KOM; PH2); Positive Dromotropic
(1; KOM; PH2); Secretolytic (1; PNC); Sedative (1; APA; CRC; PNC).
Indications (Belladonna) — Adenopathy (f; JLH); Allergy (1; APA; CRC; LAF); Arrhythmia (2;
PHR); Asthma (1; CRC; FNF; LAF; PH2); Biliary Spasm (2; KOM); Bladder Stone (f; CRC);
Brachycardia (f; CRC); Bronchosis (f; CRC; PH2); Callus (f; JLH); Cancer (f; CRC; JLH); Cancer,
breast (f; JLH); Cancer, cheek (f; JLH); Cancer, eye (f; JLH); Cancer, hand (f; JLH); Cancer, joint
(f; JLH); Cancer, lip (f; JLH); Cancer, lymph (f; JLH); Cancer, rectum (f; JLH); Cancer, tongue (f;
JLH); Cancer, uterus (f; JLH); Carcinoma (f; CRC; JLH); Cardiac Insufficiency (2; PHR); Cardiac
Palpitation (f; CRC); Cholecystosis (2; PH2); Cold (f; APA; LAF; PNC); Colic (2; CRC; KOM; LAF;
PH2); Colitis (1; APA); Constipation (1; APA; CRC); Convulsion (f; CRC); Corn (f; JLH); Cramp

(1; APA; CRC; PNC); Dermatosis (f; APA); Diarrhea (1; APA); Enterosis (2; KOM; PH2); Epilepsy
(f; CRC); Fever (f; CRC; EFS; PNC); Gastric Ulcer (f; CRC); Gastrosis (2; APA; CRC; KOM; PH2);
Gout (f; APA; CRC); Hemorrhoid (f; LAF); Hepatosis (2; PHR; PH2); Hyperacidity (1; APA);
Hyperhydrosis (f; PH2); Hyperkinesis (f; PH2); Inflammation (f; JLH; PH2); Insomnia (1; APA; CRC;
PNC); Kidney Stone (f; CRC); Low Blood Pressure (f; PNC); Mastosis (f; CRC); Meningosis (f;
PH2); Motion Sickness (1; LAF); Muscle (f; CRC); Myalgia (f; PH2); Nervousness (1; APA; CRC;
PNC); Neuralgia (1; APA; CRC; LAF); Neurosis (2; APA; PHR); Night Sweats (f; CRC); Pain (2;
CRC; FNF; LAF; KOM); Pancreatosis (f; CRC); Parkinson’s (1; APA; CRC; LAF); Parturition (1;
FNF; PNC); Pertussis (f; CRC; LAF); Respirosis (f; PH2); Rheumatism (1; APA; CRC; LAF); Scarlet
Fever (f; CRC); Sciatica (1; APA; CRC; LAF); Scirrhus (f; CRC; JLH); Seasickness (1; APA); Spasm
(f; CRC); Spermatorrhea (f; CRC); Tonsilosis (f; PH2); Tumor (f; CRC); Ulcer (1; APA); Urethrosis
(f; CRC); Virus (f; CRC); Water Retention (f; CRC; EFS); Wen (f; JLH).
Dosages (Belladonna) — Do not take (APA). Average single dose (0.05–0.1 g powdered leaf)
(KOM; PH2); maximum single dose (0.2 g powdered leaf equivalent to 0.6 mg total alkaloids)
(KOM); maximum daily dose (0.6 g powdered leaf equivalent to 1.8 mg total alkaloids) (KOM);
15–60 mg dry leaf extract (PNC); 0.5–2 ml herb tincture (PNC).
Contraindications, Interactions, and Side Effects (Belladonna) — Class 3 (AHP). “Hazards
and/or side effects not known for proper therapeutic dosages” (PH2). Commission E reports
contraindications, adverse effects, and interaction of belladonna alkaloids (AEH). Canadians do
not allow in food (Blackburn, 1993). Contraindicated: acute edema of the lungs, mechanical stenoses
of GI tract, megacolon, narrow angle glaucoma, prostate adenoma, tachycardic arrhythmias; Side
Effects: accommodation disturbances, cramps, decreased perspiration, dry mouth, dry skin, dysuria,
flushing, hallucinations, hyperthermia (KOM; PH2); Drug Interactions: increasing anticholinergic
activities of tricyclic antidepressants, amantadine and quinidine (KOM). Commission E contrasts
(Belladonna): It’s rather disconcerting that two major books, reviewed in JAMA (1999), and claiming
to represent Commission E, come out with widely different recommendations. Blumenthal et al.
1998, much better reviewed, approve belladonna leaf for spasms and colic-like pain in the areas
of the gastrointestinal tract and bile ducts. Is that the same Commission E that Fleming et al.
purports to report too? Fleming et al. contrastingly cite approval of the leaf for arrhythmia, cardiac
insufficiency (NYHA I and II), liver and gallbladder complaints, and nervous heart complaints.
Should the allopathic physician believe Blumenthal et al. (1998) or Fleming et al. (1998

Related Posts